Fig. 2: IDO activation in individuals with ASD. | Translational Psychiatry

Fig. 2: IDO activation in individuals with ASD.

From: Impact of IDO activation and alterations in the kynurenine pathway on hyperserotonemia, NAD+ production, and AhR activation in autism spectrum disorder

Fig. 2

A Plasma kynurenine (KYN) levels in controls (n = 106) and individuals with ASD (n = 271). B IDO activity estimated by the kynurenine/ tryptophan (KYN/TRP) ratio in controls (n = 106) and individuals with ASD (n = 271). C Plasma miR-153-3p levels in controls (n = 106) and individuals with ASD (n = 271). D Relationship between the KYN/TRP ratio and plasma miR-153-3P in controls (green) and individuals with ASD (magenta). E TPH activity estimated by the whole blood serotonin (5-HT)/TRP ratio in controls (n = 106) and individuals with ASD (n = 271). F Relationship between IDO (KYN/TRP) and TPH (5-HT/TRP) activities in controls (green) and individuals with ASD (magenta). G Whole blood serotonin in control rats (n = 10), DHS rats (n = 10), and DHS rats that received interferon-gamma (IFNγ) (n = 10). H IDO activity (KYN/TRP) in control (n = 10), DHS rats (n = 10), and DHS rats that received IFNγ (n = 10). Intergroup comparisons were performed using the sum-rank Wilcoxon test (A–C, E) or the Kruskal–Wallis test followed by the sum-rank Wilcoxon test corrected for multiple comparisons (G, H). Correlations (D, F) were calculated using Spearman’s correlation coefficient (ρ).

Back to article page